Should J&J’s Nipocalimab SLE Win and OTTAVA Robot Push Require Action From Johnson & Johnson (JNJ) Investors?

In early January 2026, Johnson & Johnson reported that nipocalimab (Imaavy) met primary and key secondary endpoints in the Phase 2b JASMINE trial for systemic lupus erythematosus and moved the program into Phase 3, while also advancing its MedTech ambitions with an FDA De Novo submission for the OTTAVA robotic surgical system in general surgery. This combination of a potentially first-in-class FcRn blocker in SLE and a next-generation soft-tissue surgery robot underscores Johnson &...